Details of the Drug

General Information of Drug (ID: DMHRCQI)

Drug Name

eFT226

Synonyms

Zotatifin; EFT226; UNII-2EWN8Z05CN; 2EWN8Z05CN; 2098191-53-6; EFT-226; Zotatifin [INN]; 4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)benzonitrile; 4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta[4,5]furo[3,2-c]pyridin-5a-yl)benzonitrile; Zotatifin [USAN]; Zotatifin (USAN/INN); CHEMBL4303782; SCHEMBL18864788; EX-A4623; NSC818001; NSC828584; WHO 10998; NSC-818001; NSC-828584; HY-112163; CS-0043584; D11837; Benzonitrile, 4-((5aR,6S,7S,8R,8aS)-7-((dimethylamino)methyl)-6,7,8,8a-tetrahydro-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5ah-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)-

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

487.5

Logarithm of the Partition Coefficient (xlogp)

2.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C28H29N3O5
IUPAC Name: 4-[(2S,3R,4S,5S,6R)-4-[(dimethylamino)methyl]-2,3-dihydroxy-10,12-dimethoxy-5-phenyl-7-oxa-11-azatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-6-yl]benzonitrile
Canonical SMILES: CN(C)C[C@@H]1[C@H]([C@]2([C@@]([C@@H]1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5
InChI: InChI=1S/C28H29N3O5/c1-31(2)16-20-23(18-8-6-5-7-9-18)28(19-12-10-17(15-29)11-13-19)27(33,25(20)32)24-21(36-28)14-22(34-3)30-26(24)35-4/h5-14,20,23,25,32-33H,16H2,1-4H3/t20-,23-,25-,27+,28+/m1/s1
InChIKey: QYCXWOACFWMQFO-WZWZCULESA-N

Cross-matching ID

PubChem CID: 129138801
CAS Number: 2098191-53-6
TTD ID: D8EB7G

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN eukaryotic initiation factor-4A (eIF4A)	TTIGYVZ	IF4A1_HUMAN ; IF4A2_HUMAN ; IF4A3_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04092673) Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin). U.S. National Institutes of Health.
2	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. J Med Chem. 2020 Jun 11;63(11):5879-5955.